Foghorn Therapeutics Inc Net Assets
Foghorn Therapeutics Inc net assets. Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has net assets worth $-81.04 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($203.39 Million) and total liabilities ($284.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Foghorn Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-81.04 Million |
| % of Total Assets | -39.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -212.0% |
| 10-Year Change | N/A |
| Growth Volatility | 32504.69 |
Net Assets of Foghorn Therapeutics Inc (2018–2025)
Net assets of Foghorn Therapeutics Inc from 2018 to 2025. This chart illustrates how Foghorn Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. See Foghorn Therapeutics Inc net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Foghorn Therapeutics Inc from 2018 to 2025. For live market cap and overall valuation, see Foghorn Therapeutics Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-108.50 Million | -138.31% |
| 2024-12-31 | $-45.53 Million | +41.02% |
| 2023-12-31 | $-77.19 Million | -69019.64% |
| 2022-12-31 | $112.00K | -99.88% |
| 2021-12-31 | $96.87 Million | -33.73% |
| 2020-12-31 | $146.19 Million | +266.09% |
| 2019-12-31 | $-88.02 Million | -124.11% |
| 2018-12-31 | $-39.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Foghorn Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58945900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Foghorn Therapeutics Inc Net Assets Breakdown (December 2025)
Foghorn Therapeutics Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Comprehensive Income | $24.00K | % |
| Other Components | $523.94 Million | % |
| Total Equity | $-108.50 Million | 100.00% |
Foghorn Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Foghorn Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Airtificial Intelligence Structures SA
MC:AI
|
$124.73 Million |
|
PVP Ventures Limited
NSE:PVP
|
$124.76 Million |
|
Mitrabara Adiperdana PT
JK:MBAP
|
$124.77 Million |
|
Ally Leasehold Real Estate Investment Trust
BK:ALLY
|
$124.78 Million |
|
Binh Dien Fertilizer JSC
VN:BFC
|
$124.67 Million |
|
Polski Holding Nieruchomości SA
WAR:PHN
|
$124.61 Million |
|
BAOZUN INC. A DL -0001
F:2BZ
|
$124.51 Million |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
$124.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Foghorn Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -45,528,000 to -108,500,000, a change of -62,972,000.
- Net loss of 74,283,000 reduced equity.
- New share issuances of 540,000 increased equity.
- Other comprehensive income decreased equity by 111,000.
- Other factors increased equity by 10,882,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.28 Million | -68.46% |
| Share Issuances | $540.00K | +0.5% |
| Other Comprehensive Income | $-111.00K | -0.1% |
| Other Changes | $10.88 Million | +10.03% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Foghorn Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-2.00 | $2.10 | x |
| 2019-12-31 | $-2.39 | $2.10 | x |
| 2020-12-31 | $3.97 | $2.10 | x |
| 2021-12-31 | $2.61 | $2.10 | x |
| 2022-12-31 | $0.00 | $2.10 | x |
| 2023-12-31 | $-1.84 | $2.10 | x |
| 2024-12-31 | $-0.83 | $2.10 | x |
| 2025-12-31 | $-1.72 | $2.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Foghorn Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -240.33%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-12170.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.41 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-42.33 Million |
| 2020 | -47.06% | -16000.00% | 0.00x | 1.75x | $-83.42 Million |
| 2021 | -104.59% | -7681.58% | 0.00x | 5.37x | $-111.01 Million |
| 2022 | -97208.70% | -566.23% | 0.05x | 3615.03x | $-108.88 Million |
| 2023 | 0.00% | -288.17% | 0.12x | 0.00x | $-90.71 Million |
| 2024 | 0.00% | -383.24% | 0.08x | 0.00x | $-82.07 Million |
| 2025 | 0.00% | -240.33% | 0.16x | 0.00x | $-63.43 Million |
Industry Comparison
This section compares Foghorn Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $211,904,180
- Average return on equity (ROE) among peers: 1119.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Foghorn Therapeutics Inc (FHTX) | $-81.04 Million | 0.00% | N/A | $124.71 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $27.43 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $178.43 Million | -42.75% | 0.25x | $241.32 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $181.82 Million | -56.28% | 0.31x | $15.62 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $-41.16 Million | 0.00% | 0.00x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $155.53K | 11625.26% | 37.80x | $804.31 Million |
| ABVC Biopharma Inc (ABVC) | $35.27K | -72.00% | 1.50x | $26.65 Million |
| Abivax SA American Depositary Shares (ABVX) | $17.90 Million | -209.78% | 2.98x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $3.70 Billion |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mu… Read more